Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
LEXIVA (GW433908)
DRUG
2 trials
Sponsors
GlaxoSmithKline
, ViiV Healthcare
Conditions
HIV Infection
Infection, Human Immunodeficiency Virus
Infection, Human Immunodeficiency Virus I
Phase 2
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
Completed
NCT00089583
ViiV Healthcare
Infection, Human Immunodeficiency Virus I
Start: 2004-07-31
End: 2013-07-31
Updated: 2017-03-07
Phase 3
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
Completed
NCT00085943
GlaxoSmithKline
HIV Infection, Infection, Human Immunodeficiency Virus
Start: 2004-05-31
Target: 866
Updated: 2011-05-16
Related Papers
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
2006-08-01
223 citations